"We view these successes as an indication that our product differentiation and anti-diversion messaging is beginning to resonate with managed care plans," added chief executive officer Mark A. Sirgo. He also said the company expects to see profits from Bunavial by the end of 2017. BioDelivery's stock price rose 2.52 percent, or 6 cents, from last week to $2.44. Note: This story is from the North Carolina Business News Wire, a service of UNC-Chapel Hill's School of Media and Journalism